Half-year results have been released
New investment approach in life science
Stay up-to-date with Pharma Equity Group A/S news and developments. By subscribing, you’ll be among the first to hear about exciting new investment opportunities, the development of our portfolio company Reponex Pharmaceuticals and important company announcements. To sign up, simply press the header or the button below and enter your email address in the subscription box on the page. Accept the validation mail, which is sent to your email right after signing up. We look forward to keeping you informed and engaged with the latest news from Pharma Equity Group A/S.
Presentation and valuation of Pharma Equity Group (PEG) - 30.05.2023
HC Andersen Capital has reviewed PEG and has created a 1-pager on it. In their review, they include a description of the company and what drives the value of PEG. HC Andersen Capital also looks at 3 different scenarios for the value of the company. In their base case scenario, they calculate a value of DKK 1.7 billion. dkr.
Who is Pharma Equity Group?
Pharma Equity Group, a publicly-traded entity on the Nasdaq Copenhagen Stock Exchange, focuses its core efforts on nurturing Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company. Reponex Pharmaceuticals is dedicated to developing innovative treatments for diseases with substantial societal and patient impacts, especially where current therapies lack efficacy.
Pharma Equity Group’s central mission is to support Reponex Pharmaceuticals’ growth and success. The company collaborates closely with Reponex Pharmaceuticals, tapping into the experience of its professionals in the fields of life sciences, investment, and business development.
With a particular interest in early-stage biotech firms, Pharma Equity Group recognizes the potential in Reponex Pharmaceuticals’ novel therapies. By retaining Reponex Pharmaceuticals in its portfolio, Pharma Equity Group ensures a focused and strategic approach to its advancement.
Pharma Equity Group also boasts an extensive network of industry partners and advisors, further bolstering its commitment to Reponex Pharmaceuticals’ growth. Their strategy emphasizes cost-efficiency and flexibility, enabling rapid resource mobilization, a pivotal element for the success of Reponex Pharmaceuticals’ innovative projects.
The indirect official listing of Reponex Pharmaceuticals A/S increases the Pharma Equity Group’s flexibility to fund potential acquisitions by using new shares as funding through equity funding by means of future issuances of new shares, with or without pre-emptive rights for existing shareholders, as payment.
Pharma Equity Group’s business strategy centers around a dedicated commitment to advancing its subsidiary, Reponex Pharmaceuticals A/S. With a tailored investment approach, our primary focus is on driving the growth and prosperity of Reponex Pharmaceuticals through strategic investments. We recognize the exceptional value of Reponex Pharmaceuticals within our portfolio and, as such, direct our resources towards supporting the progression of their clinical candidates and innovative therapies designed to address unmet medical needs and enhance patient outcomes.